We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Presents Vivalytic Universal, Fully Automated All-in-One Solution for Molecular Diagnostics at ECCMID 2022

By LabMedica International staff writers
Posted on 25 Apr 2022

Randox Laboratories (Crumlin, UK) presented the Vivalytic Analyzer, an all-in-one solution for PCR rapid tests, developed in partnership with Bosch Healthcare Solutions GmbH (Waiblingen, Germany), at ECCMID 2022. More...

The event which took place in Lisbon, Portugal from April 23-26 offered a wide range of sessions including keynotes, symposia, poster sessions, educational workshops, meet-the-expert sessions and more.

The Vivalytic platform is a universal, fully automated all in one solution for molecular diagnostics. It is a cartridge-based platform enabling Hi-Plex and Lo-Plex testing and consolidates the full molecular workflow into a small benchtop platform, capable of extraction, PCR amplification and detection. Randox multiplex Biochip Technology powers Vivalytic enabling multiple results from one patient sample. Randox patented Biochip Technology allows simultaneous detection of multiple targets from a single patient sample. The biochip detection system is based on a chemiluminescent signal, this is the emission of light, without heat, as a result of a chemical reaction. Each biochip is prefabricated with spatially discrete testing regions (DTRs). Each DTR represents an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest. The Hi-Plex capabilities of Biochip Technology eliminates the need to run multiple time consuming and sample intensive assays.

The Vivalytic Analyzer unites a wide variety of innovative technologies in one compact device. With only a touch display, a slot for inserting the test cartridge, a button and a scanner, the Analyzer is very intuitive to use. This minimalistic design makes the Vivalytic system very user-friendly: medical professionals require only minimal training to be able to safely operate the Analyzer. Different types of samples can be tested fully automated with the Vivalytic Analyzer. The innovative technology reduces the need for manual preparation. The Analyzer takes over this task before the analysis and evaluation takes place. Depending on the complexity of the test, a PCR test with the Vivalytic Analyzer can take as little as half an hour.

Related Links:
Randox Laboratories
Bosch Healthcare Solutions GmbH


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
New
Toxoplasma Gondii Test
Toxo IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.